TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs.… EP News Bureau Jun 3, 2024 First and only EGFR inhibitor and targeted treatment to show benefit in stage III setting, extending progression-free survival…
